REGENERON PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
REGENERON PHARMACEUTICALS, INC. (REGN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $242.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $242.50M, a 4.86% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $246.90M, a 4.63% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $241.00M, a 4.60% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $254.90M, a 10.83% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.00B, a 0.47% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $996.90M, a 11.47% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $894.30M, a 21.21% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $737.80M, a 23.13% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $242.50M 10-Q · filed 2026-07-30 | $489.40M derived: sum of 2 quarters · filed 2026-07-30 | |||
| 2026-03-31 | $246.90M 10-Q · filed 2026-07-30 | ||||
| 2025-12-31 | $1.00B 10-K · filed 2026-02-04 | ||||
| 2025-09-30 | $241.00M 10-Q · filed 2025-10-28 | $495.90M derived: sum of 2 quarters · filed 2026-07-30 | $754.80M derived: sum of 3 quarters · filed 2026-07-30 | ||
| 2025-06-30 | $254.90M 10-Q · filed 2026-07-30 | $513.80M derived: sum of 2 quarters · filed 2026-07-30 | |||
| 2025-03-31 | $258.90M 10-Q · filed 2026-07-30 | ||||
| 2024-12-31 | $996.90M 10-K · filed 2026-02-04 | ||||
| 2024-09-30 | $230.40M 10-Q · filed 2025-10-28 | $460.40M derived: sum of 2 quarters · filed 2025-10-28 | $693.70M derived: sum of 3 quarters · filed 2025-10-28 | ||
| 2024-06-30 | $230.00M 10-Q · filed 2025-10-28 | $463.30M derived: sum of 2 quarters · filed 2025-10-28 | |||
| 2024-03-31 | $233.30M 10-Q · filed 2025-10-28 | ||||
| 2023-12-31 | $894.30M 10-K · filed 2026-02-04 | ||||
| 2023-09-30 | $207.40M 10-Q · filed 2024-10-31 | $415.40M derived: sum of 2 quarters · filed 2024-10-31 | $652.80M derived: sum of 3 quarters · filed 2024-10-31 | ||
| 2023-06-30 | $208.00M 10-Q · filed 2024-10-31 | $445.40M derived: sum of 2 quarters · filed 2024-10-31 | |||
| 2023-03-31 | $237.40M 10-Q · filed 2024-10-31 | ||||
| 2022-12-31 | $737.80M 10-K · filed 2025-02-05 | ||||
| 2022-09-30 | $171.10M 10-Q · filed 2023-11-02 | $337.10M derived: sum of 2 quarters · filed 2023-11-02 | $503.00M derived: sum of 3 quarters · filed 2023-11-02 | ||
| 2022-06-30 | $166.00M 10-Q · filed 2023-11-02 | $331.90M derived: sum of 2 quarters · filed 2023-11-02 | |||
| 2022-03-31 | $165.90M 10-Q · filed 2023-11-02 | ||||
| 2021-12-31 | $599.20M 10-K · filed 2024-02-05 | ||||
| 2021-09-30 | $136.40M 10-Q · filed 2022-11-03 | $272.30M derived: sum of 2 quarters · filed 2022-11-03 | $407.90M derived: sum of 3 quarters · filed 2022-11-03 | ||
| 2021-06-30 | $135.90M 10-Q · filed 2022-11-03 | $271.50M derived: sum of 2 quarters · filed 2022-11-03 | |||
| 2021-03-31 | $135.60M 10-Q · filed 2022-11-03 | ||||
| 2020-12-31 | $442.90M 10-K · filed 2023-02-06 | ||||
| 2020-09-30 | $104.60M 10-Q · filed 2021-11-04 | $209.80M derived: sum of 2 quarters · filed 2021-11-04 | $317.80M derived: sum of 3 quarters · filed 2021-11-04 | ||
| 2020-06-30 | $105.20M 10-Q · filed 2021-11-04 | $213.20M derived: sum of 2 quarters · filed 2021-11-04 | |||
| 2020-03-31 | $108.00M 10-Q · filed 2021-11-04 | ||||
| 2019-12-31 | $466.90M 10-K · filed 2022-02-07 | ||||
| 2019-09-30 | $112.70M 10-Q · filed 2020-11-05 | $221.90M derived: sum of 2 quarters · filed 2020-11-05 | $336.70M derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $109.20M 10-Q · filed 2020-11-05 | $224.00M derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | $114.80M 10-Q · filed 2020-11-05 | ||||
| 2018-12-31 | $444.80M 10-K · filed 2021-02-08 | ||||
| 2018-09-30 | $116.50M 10-Q · filed 2019-11-05 | $229.60M derived: sum of 2 quarters · filed 2019-11-05 | $315.40M derived: sum of 3 quarters · filed 2019-11-05 | ||
| 2018-06-30 | $113.10M 10-Q · filed 2019-11-05 | $198.90M derived: sum of 2 quarters · filed 2019-11-05 | |||
| 2018-03-31 | $85.80M 10-Q · filed 2019-11-05 | ||||
| 2017-12-31 | $524.60M 10-K · filed 2020-02-07 | $524.53M 10-K · filed 2018-02-08 | |||
| 2016-12-31 | $574.90M 10-K · filed 2019-02-07 | $574.89M 10-K · filed 2017-02-09 | |||
| 2015-12-31 | $464.02M 10-K · filed 2018-02-08 | ||||
| 2014-12-31 | $97.12M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $171.68M derived: sum of 2 quarters · filed 2017-02-09 | $243.83M derived: sum of 3 quarters · filed 2017-02-09 | $326.81M 10-K · filed 2017-02-09 | $312.30M 10-K · filed 2015-02-12 |
| 2014-09-30 | $74.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $146.71M derived: sum of 2 quarters · filed 2014-11-04 | $229.69M 10-Q · filed 2014-11-04 | $301.96M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2014-06-30 | $72.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $155.14M 10-Q · filed 2014-08-05 | $227.41M derived: sum of 3 quarters · filed 2016-02-11 | $273.49M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2014-03-31 | $82.98M 10-Q · filed 2014-05-08 | $155.25M derived: sum of 2 quarters · filed 2016-02-11 | $201.33M derived: sum of 3 quarters · filed 2016-02-11 | $246.51M derived: sum of 4 quarters · filed 2016-02-11 | |
| 2013-12-31 | $72.27M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $118.35M derived: sum of 2 quarters · filed 2016-02-11 | $163.53M derived: sum of 3 quarters · filed 2016-02-11 | $217.08M 10-K · filed 2016-02-11 | $200.10M 10-K · filed 2014-02-13 |
| 2013-09-30 | $46.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $91.25M derived: sum of 2 quarters · filed 2014-11-04 | $144.81M 10-Q · filed 2014-11-04 | $175.48M derived: sum of 4 quarters · filed 2015-02-12 | |
| 2013-06-30 | $45.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $98.73M 10-Q · filed 2014-08-05 | $129.40M derived: sum of 3 quarters · filed 2015-02-12 | $150.06M derived: sum of 4 quarters · filed 2015-02-12 | |
| 2013-03-31 | $53.55M 10-Q · filed 2014-05-08 | $84.23M derived: sum of 2 quarters · filed 2015-02-12 | $104.89M derived: sum of 3 quarters · filed 2015-02-12 | $124.29M derived: sum of 4 quarters · filed 2015-02-12 | |
| 2012-12-31 | $30.67M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $51.33M derived: sum of 2 quarters · filed 2015-02-12 | $70.73M derived: sum of 3 quarters · filed 2015-02-12 | $94.18M 10-K · filed 2015-02-12 | |
| 2012-09-30 | $20.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $40.06M derived: sum of 2 quarters · filed 2013-11-05 | $63.51M 10-Q · filed 2013-11-05 | $79.35M derived: sum of 4 quarters · filed 2014-02-13 | |
| 2012-06-30 | $19.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $42.85M 10-Q · filed 2013-08-06 | $58.69M derived: sum of 3 quarters · filed 2014-02-13 | $72.07M derived: sum of 4 quarters · filed 2014-02-13 | |
| 2012-03-31 | $23.45M 10-Q · filed 2013-05-03 | $39.29M derived: sum of 2 quarters · filed 2014-02-13 | $52.67M derived: sum of 3 quarters · filed 2014-02-13 | $65.16M derived: sum of 4 quarters · filed 2014-02-13 | |
| 2011-12-31 | $15.84M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $29.22M derived: sum of 2 quarters · filed 2014-02-13 | $41.71M derived: sum of 3 quarters · filed 2014-02-13 | $56.61M 10-K · filed 2014-02-13 | |
| 2011-09-30 | $13.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $25.87M derived: sum of 2 quarters · filed 2012-10-24 | $40.77M 10-Q · filed 2012-10-24 | ||
| 2011-06-30 | $12.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $27.39M 10-Q · filed 2012-07-25 | |||
| 2011-03-31 | $14.90M 10-Q · filed 2012-04-26 | ||||
| 2010-12-31 | $39.90M 10-K · filed 2013-02-15 | ||||
| 2010-03-31 | $8.83M 10-Q · filed 2011-05-03 | ||||
| 2009-12-31 | $31.26M 10-K · filed 2012-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |